Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB

Patent metadata

Field	Value
Publication number	US-11851652-B2
Application number	US-202217694361-A
Country	US
Kind code	B2
Filing date	Mar 14, 2022
Priority date	Apr 6, 2015
Publication date	Dec 26, 2023
Grant date	Dec 26, 2023

Abstract

Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

First claim

What is claimed is:

1. A primary CD34+hematopoietic stem or progenitor cell (HSPC) comprising:
(a) a modified single guide RNA (sgRNA) comprising a nucleotide sequence that is complementary to a sequence within the HBB gene, wherein the modified sgRNA sequence is selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO: 7;
(b) a Cas polypeptide, an mRNA encoding the Cas polypeptide, or a recombinant expression vector comprising a nucleotide sequence encoding the Cas polypeptide.

2. The primary CD34 + hematopoietic stem or progenitor cell of claim 1 , wherein the primary CD34 + hematopoietic stem or progenitor cell comprises a mutation in the HBB gene responsible for sickle cell anemia.

3. The primary CD34 + hematopoietic stem or progenitor cell of claim 1 , wherein the primary CD34 + hematopoietic stem or progenitor cell comprises a mutation in the HBB gene responsible for thalassemia.

4. The primary CD34 + hematopoietic stem or progenitor cell of claim 1 , further comprising a recombinant donor repair template.

5. The primary CD34 + hematopoietic stem or progenitor cell of claim 4 , wherein the recombinant donor repair template comprises two nucleotide sequences comprising two non-overlapping, homologous portions, wherein one of the two homologous portions is located at the 5′ end and the other homologous portion is located at the 3′ end of the recombinant donor template, wherein each homologous portion is homologous to a corresponding region of the HBB gene to undergo genome editing.

6. The primary CD34 + hematopoietic stem or progenitor cell of claim 4 , wherein the recombinant donor repair template comprises a synthetic single-stranded oligodeoxynucleotide (ssODN) template comprising a nucleotide sequence encoding a mutation to correct a single nucleotide polymorphism (SNP) in the HBB gene and two nucleotide sequences comprising two non-overlapping, homologous portions that are homologous to corresponding regions of the HBB gene, wherein one of the two homologous portions is located at the 5′ end and the other homologous portion is located at the 3′ end of the recombinant donor template.

7. The primary CD34 + hematopoietic stem or progenitor cell of claim 1 , wherein the Cas polypeptide is endonuclease-deficient.

8. The primary CD34 + hematopoietic stem or progenitor cell of claim 1 , wherein the Cas polypeptide is a Cas9 polypeptide, a variant thereof, or a fragment thereof.

9. The primary CD34 + hematopoietic stem or progenitor cell of claim 1 , wherein the Cas polypeptide is a nickase.

10. The primary CD34 + hematopoietic stem or progenitor cell of claim 1 , wherein the primary cell comprises mRNA encoding the Cas polypeptide.

11. A population of primary CD34 + hematopoietic stem and progenitor cell (HSPCs) comprising the primary CD34 + hematopoietic stem or progenitor cell of claim 1 .

12. The population of primary CD34 + HSPCs of claim 11 , wherein the population of primary CD34 + HSPCs is isolated from a subject having sickle cell anemia or thalassemia.

13. The population of primary CD34 + HSPCs of claim 11 , wherein the modified sgRNA induces gene editing of HBB in at least about 30% of the population of primary CD34 + HSPCs.

14. A primary CD34 + hematopoietic stem or progenitor cell comprising a ribonucleoprotein (RNP) complex comprising:
(a) a modified single guide RNA (sgRNA) comprising a nucleotide sequence that is complementary to a sequence within the HBB gene, wherein the modified sgRNA sequence is selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO: 7; and (b) a Cas polypeptide.

15. The primary CD34 + hematopoietic stem or progenitor cell of claim 14 , wherein the primary CD34 + hematopoietic stem or progenitor cell comprises a mutation in the HBB gene responsible for sickle cell anemia.

16. The primary CD34 + hematopoietic stem or progenitor cell of claim 14 , wherein the primary CD34 + hematopoietic stem or progenitor cell comprises a mutation in the HBB gene responsible for thalassemia.

17. The primary CD34 + hematopoietic stem or progenitor cell of claim 14 , further comprising a recombinant donor repair template.

18. The primary CD34 + hematopoietic stem or progenitor cell of claim 17 , wherein the recombinant donor repair template comprises two nucleotide sequences comprising two non-overlapping, homologous portions, wherein one of the two homologous portions is located at the 5′ end and the other homologous portion is located at the 3′ end of the recombinant donor template, wherein each homologous portion is homologous to a corresponding region of the HBB gene to undergo genome editing.

19. The primary CD34 + hematopoietic stem or progenitor cell of claim 17 , wherein the recombinant donor repair template comprises a synthetic single-stranded oligodeoxynucleotide (ssODN) template comprising a nucleotide sequence encoding a mutation to correct a single nucleotide polymorphism (SNP) in the HBB gene and two nucleotide sequences comprising two non-overlapping, homologous portions that are homologous to corresponding regions of the HBB gene, wherein one of the two homologous portions is located at the 5′ end and the other homologous portion is located at the 3′ end of the recombinant donor template.

20. A population of primary CD34 + HSPCs comprising the primary CD34 + hematopoietic stem or progenitor cell of claim 14 .

21. The population of primary CD34 + HSPCs of claim 20 , wherein the population of primary CD34 + HSPCs is isolated from a subject having sickle cell anemia or thalassemia.

22. The population of primary CD34 + HSPCs of claim 20 , wherein the modified sgRNA induces gene editing of HBB in at least about 30% of the population of primary CD34 + HSPCs.

Assignees

• Univ Leland Stanford Junior
• The Board Of Trustees Of The Leland Stanford Junior
• Univ And Agilent Technologies Inc

Inventors

• Porteus Matthew H
• Hendel Ayal
• Clark Joe
• Bak Rasmus O
• Ryan Daniel E
• Dellinger Douglas J
• Kaiser Robert
• Myerson Joel

Classifications

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C12N9/222

  Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes · CPC title

• C12N15/11 Primary

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N9/96

  Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates · CPC title